Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Product Specifications

CAS Number

[204656-20-2]

UNSPSC

12352209

Hazard Statement

H315, H319, H335

Target

GCGR; GLP Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Liraglutide.html

Purity

99.85

Solubility

0.1 M NaOH : 12.5 mg/mL (adjust pH to 8 with 0.1 M NaOH) |H2O : 9.52 mg/mL (adjust pH to 3 with 1 M HCl)

Smiles

[His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{Lys(gGlu-C16acid)}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly]

Molecular Formula

C172H265N43O51

Molecular Weight

3751.20

Precautions

H315, H319, H335

References & Citations

[1]Wang Y, et al. Transformation of oligomers of lipidated peptide induced by change in pH.Mol Pharm. 2015 Feb 2;12 (2) :411-9.|[2]Wang YG, et al. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway.J Geriatr Cardiol. 2015 Jul;12 (4) :410-416.